From: Trends and advances in tumor immunology and lung cancer immunotherapy
Vaccine | Phase | Pt No. | Stages | Results |
---|---|---|---|---|
MAGE-A3 | II | 182 | IB/II | DFI: (HR: 0.75, 95 % CI, 0.46 to 1.23; two-sided P = .254); DFS: (HR: 0.76; 95 % CI, 0.48 to 1.21; P = .248); OS: (HR, 0.81; 95 % CI, 0.47 to 1.40; P = .454) [59]. |
BLP25 | II | 171 | IIIB/IV | Median OS: 17.4 months with L-BLP25/BSC vs 13.0 months with BSC alone [68]. Subset analysis (n = 65): Median OS: 30.6 months with L-BLP25/BSC vs 13.3 months with BSC alone [69]. |
III | 1239 | III | Median OS: 25.6Â months with L-BLP25 vs 22.3Â months with placebo [70]. Subset analysis (patients with previous chemoradiotherapy): Median OS: 30.8Â months with L-BLP25 vs 20.6Â months with placebo [70]. | |
Belagenpumatucel-L | II | 75 | II/IV | Estimated 2-years survival: 52Â % with high doses vs 20Â % with low doses [75]. |
III | 532 | III/IV | Median OS: 20.3Â months with belagenpumatucel-L vs 17.8Â months with placebo [76]. Subset analysis (patients with pretreatment radiation): Median OS: 40.1Â months with belagenpumatucel-L vs 10.3Â months with placebo [76]. | |
CIMAvax EGF | II | 80 | IIIB/IV | Median survival: 11.7Â months with GAR vs 3.6Â months with PAR [81]. |
TG4010 | II | 148 | IIIB/IV | 6-months PFS: 43.2Â % with TG4010/chemotherapy vs 35.1Â % with chemotherapy alone [84]. |